Aterian Investment Partners has announced the acquisition of Contract Pharmaceuticals Ltd. Canada, a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.

Based in Mississauga, Ontario, Canada, CPL is an industry leader with longstanding relationships with 15 of the top 20 global pharmaceutical companies. The Company supports its customers through its FDA and Health Canada-registered facilities and sells into North America, the European Union, Japan, Australia, Mexico, Brazil and the Middle East.

“We are excited to have successfully closed this transaction. With Aterian’s investment in people, technology and processes, CPL is equipped and ready to enter its next phase of growth and to drive industry transformation by providing further value to customers,” said the Aterian team.

“With Aterian’s backing, we are laser-focused on innovation, growth and delighting our customers to further expand our unmatched position in the non-sterile liquid and topical drug products space,” said Jan Sahai, CEO of CPL.

“This collaboration undoubtedly strengthens our positioning in serving our customers and being the trusted partner to pharmaceutical companies around the world,” Sahai added.

Jay Taunk, Principal at Aterian, added, “CPL represents Aterian’s thirteenth investment in the life sciences, personal care and nutrition segments. We are thrilled to support CPL and look forward to working with the management team to continue the Company’s growth trajectory.”